As was already the case before the Covid-19 pandemic, dementia was the third-most common cause at 8.8%, the Federal Statistical Office (FSO) said on Monday. Respiratory diseases (6.1%) and Covid itself (5.5%) were next-most lethal.
Last year, the standardised mortality rate was 504 per 100,000 for men – with an average age at death of 77 – and 352 per 100,000 for women, with an average age of 83.
Cardiovascular diseases accounted for 9,512 deaths (26.1%) among men and 10,951 (28.8%) among women. The standardised rate increased by 0.5% for the former (+398 deaths) and by 1% for the latter (+420 deaths). The average age of men who died from such a disease was 81.4, compared to 87.4 for women.
In 2022, 17,220 people died of cancer. The disease proved fatal for 9,310 men, with an average age of 75, and 7,910 women, also with an average age of 75. Compared to 2021, the standardised rate for men decreased by 2.3%, but with 45 more deaths. For women, the rate increased or 2.1% (+295 deaths). The most deadly form was lung cancer.
Last year, 4,114 people died as a result of Covid-19, with an average age of 82 for men and 85 for women. Compared to the previous year, the standardised rate decreased by 34.1% (-949 deaths) for the former and by 33.6% (-894) for the latter. Six deaths were also indicated as being due to side effects of the coronavirus vaccination.
Road traffic accidents caused 233 deaths, 173 of whom were men with an average age of 54, and 60 women with an average age of 53. Here, the standardised mortality rate for men (three per 100,000) was three times higher than for women (one per 100,000). For the latter there was a 71% increase (+17 deaths) and for men a 13% increase (also +17).
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
EU Commission president says Swiss-EU deal is ‘historic’ agreement
This content was published on
At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".
Switzerland and EU reach deal on future bilateral relations
This content was published on
Switzerland and the European Union have announced a political agreement to update their trading relationship after almost a decade of difficult talks.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.